Request Sample Inquiry
Orphan Drugs Market

Orphan Drugs Market

Orphan Drugs Market Global Industry Assessment & Forecast

# Pages:


Base Year:


Nov - 2021


Report Code:


Segments Covered
  • By Disease Type Oncologic Diseases, Metabolic Diseases, Hematologic & Immunologic Diseases, Infectious Diseases, Neurologic Diseases, Other Rare Diseases
  • By Indication Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Cystic Fibrosis, Glioma, Pancreatic Cancer, Ovarian Cancer, Multiple Myeloma, Duchenne Muscular Dystrophy, Graft vs Host Disease, Renal Cell Carcinoma, Others
Forecast YearsForecast Years: 2021 - 2028
Historical YearsHistorical Years: 2016 - 2020
Revenue 2021Revenue 2021: 112.36 Billion
Revenue 2028Revenue 2028: 3199.3 Billion
Revenue CAGRRevenue CAGR (2021 - 2028): 7.4
Fastest Growing Region Fastest Growing Region (2022 - 2028) North America
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report
  • Go To Market Strategy
  • Region Specific Market Dynamics
  • Region Level Market Share
  • Import Export Analysis
  • Production Analysis
  • Others Request Customization Speak To Analyst
Frequently Asked Question
  • The global Orphan Drugs valued at 112.36 Billion in 2020 and is expected to reach 3199.3 Billion in 2028 growing at a CAGR of 7.4%.

  • The prominent players in the market are RegeneRX Biopharmaceuticals Inc., F.Hoffman-La Roche AG, Pfizer Inc., Shire PLC, AbbVie Inc., Alexion, Bayer, Celgene Corporation, Johnson & Johnson Services Inc., Sanofi, Novartis AG, Merck & Co. Inc., Amryt Pharma PLC, Brisol-Myers Squibb Company..

  • The market is project to grow at a CAGR of 7.4% between 2021 and 2028.

  • The driving factors of the Orphan Drugs include

    • Demand has increased substantial for the orphan drugs due to surge in occurrence of rare diseases. Furthermore, the increase in awareness with respect to rare diseases among the populace, rise in investment in R&D, and drug development is fueling the market growth.
    • Rising healthcare spending nd improving healthcare infrastrcture is another driving factor for the market.

  • North America was the leading regional segment of the Orphan Drugs in 2020.